The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
Read Full Article
#Moderna #PandemicFlu #VaccineDevelopment #USGovernment #PublicHealth
Read Full Article
#Moderna #PandemicFlu #VaccineDevelopment #USGovernment #PublicHealth
AP News
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine.
👍2🤬2
A Phase 1/2 trial of Moderna’s mRNA-1083 found strong immune responses against both viruses, similar to existing vaccines. Most side effects were mild.
Read Full Article
#Moderna #mRNA1083 #VaccineResearch #ImmuneResponse #ClinicalTrials
Read Full Article
#Moderna #mRNA1083 #VaccineResearch #ImmuneResponse #ClinicalTrials
Nature
mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial
Nature Medicine - An interim analysis shows that a new mRNA influenza and SAR-CoV-2 combination vaccine is safe and triggers an encouraging immune response.
🤡4👏3🤣2🤮1🖕1
FDA refuses to review Moderna’s mRNA flu vaccine
Read Full Article
#FDA #Moderna #mRNA #FluVaccine #News
Read Full Article
#FDA #Moderna #mRNA #FluVaccine #News
Science News
FDA refuses to review Moderna’s mRNA flu vaccine Read Full Article #FDA #Moderna #mRNA #FluVaccine #News
💉 The FDA has refused to review Moderna's application for its mRNA flu vaccine, mRNA-1010, citing issues with the design of its Phase 3 trial, specifically the comparator vaccine used.
🤔 Moderna stated they were surprised by the FDA's decision, as the trial design, which compared mRNA-1010 to licensed vaccines like GlaxoSmithKline's Fluarix, had been reviewed and accepted by the FDA on at least two prior occasions in April 2024 and August 2025.
🔬 The Phase 3 trial for mRNA-1010 enrolled nearly 41,000 participants and found the mRNA vaccine to be superior to the comparator vaccines.
#Moderna #FDA #VaccineNews
🤔 Moderna stated they were surprised by the FDA's decision, as the trial design, which compared mRNA-1010 to licensed vaccines like GlaxoSmithKline's Fluarix, had been reviewed and accepted by the FDA on at least two prior occasions in April 2024 and August 2025.
🔬 The Phase 3 trial for mRNA-1010 enrolled nearly 41,000 participants and found the mRNA vaccine to be superior to the comparator vaccines.
#Moderna #FDA #VaccineNews